Psychedelic pharmaceutical company focusing on creating optimized and patentable next-generation psychedelic compounds Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) has entered into a manufacturing agreement with a leading contract development and manufacturing organization (CDMO) for the production of pharmaceutical grade batches of Mindsets’s next-generation psilocybin drug candidate MSP-1014.
The chief executive officer of Mindset, James Lanthier, says during pre-clinical trials MSP-1014 has shown improved efficacy and safety compared to first-generation psilocybin. The drug candidate has also shown pharmacological diversity making it a potentially suitable for both in clinic treatment approaches and as a take-home medicine.
“Following our co-development announcement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for our short-duration compounds (Mindset Families 2 & 4), we continue to receive interest from potential partners for our wider portfolio of differentiated next-generation drug candidates. As such, our manufacturing agreement with a leading CDMO positions MSP-1014 well for partnership opportunities to advance this optimized compound to human clinical trials,” added the CEO.